Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06607978
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-19
Brief Title:
Relationship of Noninvasive Assessment of Central BP With 10 Years Atherosclerotic CVD in Subclinical Hypothyroidism
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Relationship of Noninvasive Assessment of Central Blood Pressure With 10 Years Atherosclerotic Cardiovascular Disease in Subclinical Hypothyroidism
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
verify Relationship of noninvasive assessment of central arterial blood pressure with 10 years Atherosclerotic Cardiovascular disease ASCVD in Subclinical hypothyroidism
Detailed Description:
Subclinical hypothyroidism SCH characterized by elevated thyrotropin TSH levels with normal free thyroxine T3T4 concentrations is a prevalent disorder affecting approximately 10 of the adult population It has been increasingly recognized for its potential impact on cardiovascular health A 10-year follow-up study highlighted a significant association between elevated serum TSH levels and increased cardiovascular CV risk independent of conventional risk factors And it demonstrated its association with hypercholesterolemia and atherosclerosis as the leading risk of CVD Moreover in a recent meta-analysis subclinical hypothyroidism was shown actually be correlated with an increased risk of CVD and mortality
Monitoring thyroid function underscores the potential importance of cardiovascular CV risk assessment for patients with subclinical hypothyroidism SCH Incorporating thyroid function tests such as TSH and free thyroxine FT4 levels alongside non-invasive central arterial blood pressure monitoring provides a comprehensive understanding of a patientamp39s CV risk This integrated approach enables early identification and targeted interventions ultimately improving patient outcomes and reducing the incidence of CVD among those with SCH
One of the earliest functional changes underlying ASCVD is Arterial stiffening it reflects a variety of pathologies including atherosclerosis As an important determinant of cardiovascular health arterial stiffness can contribute to increased blood pressure and reduces vesselsamp39 capacity to buffer the pulsatile flow when the heart contracts which are significant risk factors for predicting ASCVD
For continuous non-invasive central arterial blood pressure monitoring the auscultatory method or The Oscillometric technique can be used These methods provide valuable insights into the health of the central arteries which are crucial in understanding the cardiovascular risk profile of patients with SCH
Monitoring thyroid function underscores the potential importance of cardiovascular CV risk assessment for patients with subclinical hypothyroidism SCH Incorporating thyroid function tests such as TSH and free thyroxine FT4 levels alongside non-invasive central arterial blood pressure monitoring provides a comprehensive understanding of a patientamp39s CV risk This integrated approach enables early identification and targeted interventions ultimately improving patient outcomes and reducing the incidence of CVD among those with SCH
One of the earliest functional changes underlying ASCVD is Arterial stiffening it reflects a variety of pathologies including atherosclerosis As an important determinant of cardiovascular health arterial stiffness can contribute to increased blood pressure and reduces vesselsamp39 capacity to buffer the pulsatile flow when the heart contracts which are significant risk factors for predicting ASCVD
For continuous non-invasive central arterial blood pressure monitoring the auscultatory method or The Oscillometric technique can be used These methods provide valuable insights into the health of the central arteries which are crucial in understanding the cardiovascular risk profile of patients with SCH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None